Lifesci Capital Issues Pessimistic Outlook for MPLT Earnings

Maplight Therapeutics, Inc. (NASDAQ:MPLT) – Investment analysts at Lifesci Capital cut their Q2 2026 EPS estimates for shares of Maplight Therapeutics in a report issued on Friday, May 15th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings of ($1.38) per share for the quarter, down from their previous estimate of ($1.02). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Maplight Therapeutics’ current full-year earnings is ($4.04) per share. Lifesci Capital also issued estimates for Maplight Therapeutics’ Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.45) EPS and FY2026 earnings at ($5.56) EPS.

Several other brokerages have also recently commented on MPLT. TD Cowen initiated coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating on the stock. Wall Street Zen cut shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. HC Wainwright started coverage on shares of Maplight Therapeutics in a report on Monday, May 4th. They issued a “buy” rating and a $45.00 target price on the stock. Needham & Company LLC started coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.43.

Maplight Therapeutics Stock Down 7.8%

MPLT opened at $26.50 on Tuesday. The company has a market cap of $1.13 billion and a PE ratio of -0.67. Maplight Therapeutics has a 12 month low of $12.24 and a 12 month high of $33.28. The company has a fifty day moving average of $24.41.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio acquired a new position in Maplight Therapeutics in the 4th quarter valued at about $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $70,000. New York State Common Retirement Fund acquired a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $93,000. MetLife Investment Management LLC acquired a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $172,000. Finally, Walleye Capital LLC acquired a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $205,000.

Insiders Place Their Bets

In related news, CEO Christopher A. Kroeger sold 118,235 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $27.19, for a total value of $3,214,809.65. Following the transaction, the chief executive officer owned 1,394,094 shares in the company, valued at approximately $37,905,415.86. This represents a 7.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Erin Pennock Foff sold 24,052 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total transaction of $691,735.52. Following the completion of the transaction, the insider owned 350,497 shares in the company, valued at approximately $10,080,293.72. This trade represents a 6.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have acquired 25,000 shares of company stock worth $441,168 and have sold 509,439 shares worth $14,339,878. Corporate insiders own 3.80% of the company’s stock.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.